12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AcipHex rabeprazole regulatory update

FDA issued a safety communication to warn that prescription and OTC proton pump inhibitors (PPI) may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD). The agency said a diagnosis of CDAD should be considered for those receiving PPIs with diarrhea that does not improve. FDA said that it is working with manufacturers to include the increased risk in...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >